A Comprehensive Review : Solid Dispersion Technology for Enhancement of Gliclazide Solubility and Dissolution

SOLID DISPERSION TECHNOLOGY

Solid dispersion (SD) technology is one of the most effective pharmaceutical approaches for enhancing the solubility, dissolution rate, and oral bioavailability of poorly water-soluble drugs. The concept was first introduced by Chiou and Riegelman in 1971, who defined solid dispersions as the dispersion of one or more active pharmaceutical ingredients in an inert carrier or matrix in the solid state. Since then, solid dispersion technology has become an important formulation strategy for Biopharmaceutics Classification System (BCS) Class II and Class IV drugs, where poor aqueous solubility limits oral absorption ⁽¹¹⁾

The principle of solid dispersion involves dispersing a poorly soluble drug at the molecular, colloidal, or particulate level within a hydrophilic polymeric carrier. The hydrophilic carrier dissolves rapidly in gastrointestinal fluids, increasing drug wettability, reducing particle size, enhancing surface area, decreasing crystallinity, and often converting the drug into an amorphous state. These physicochemical changes markedly improve drug dissolution and subsequently increase oral bioavailability ⁽¹²⁾

Solid dispersion systems are widely employed because they are relatively simple to formulate, economical, scalable, and compatible with conventional pharmaceutical manufacturing processes. Hydrophilic carriers such as polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), poloxamers, Soluplus®, copovidone, and Eudragit® are commonly used due to their excellent solubilizing ability and capacity to stabilize amorphous drug forms ⁽¹³⁾

For poorly soluble drugs such as gliclazide, dissolution is the rate-limiting step in gastrointestinal absorption. Solid dispersion technology significantly enhances drug dissolution by improving wettability, reducing particle aggregation, increasing porosity, promoting molecular dispersion, and preventing recrystallization. Consequently, this technique has been extensively investigated for improving the therapeutic performance of gliclazide and many other BCS Class II drugs.

Solid dispersions are generally classified into first-, second-, third-, and fourth-generation systems based on the nature of the carrier employed. First-generation solid dispersions utilize crystalline carriers, second-generation systems employ amorphous polymeric carriers, third-generation systems incorporate surfactants or self-emulsifying carriers to improve dissolution and stability, while fourth-generation solid dispersions are designed for controlled or sustained drug release.

The mechanisms responsible for enhanced drug dissolution from solid dispersions include molecular dispersion of the drug, particle size reduction to the molecular level, improved wettability, increased porosity, amorphization, inhibition of crystal growth, enhanced surface free energy, and stabilization of supersaturated drug solutions. These mechanisms collectively contribute to rapid dissolution, improved gastrointestinal absorption, enhanced oral bioavailability, reduced dose variability, and superior therapeutic efficacy.

METHODS OF PREPARATION OF SOLID DISPERSION

Several techniques have been developed for the preparation of solid dispersions. The selection of an appropriate method depends on the physicochemical properties of the drug and carrier, thermal stability, solvent compatibility, desired drug release profile, and industrial scalability.

1. Fusion (Melting) Method The fusion or melting method is the simplest and oldest technique for preparing solid dispersions. In this method, the hydrophilic carrier is heated above its melting point until a homogeneous molten mass is obtained. The drug is then incorporated into the molten carrier with continuous stirring to ensure uniform dispersion. The resulting melt is rapidly cooled to room temperature or on an ice bath to prevent drug recrystallization. The solidified mass is crushed, pulverized, and sieved to obtain particles of the desired size.

This method is suitable for thermally stable drugs and carriers such as polyethylene glycol (PEG), poloxamers, and Gelucire®. It is solvent-free, economical, and easy to scale up; however, it is not suitable for thermolabile drugs due to the possibility of thermal degradation.⁽¹⁴⁾

2. Solvent Evaporation Method

In the solvent evaporation method, both the drug and hydrophilic carrier are dissolved in a common volatile solvent such as ethanol, methanol, acetone, or chloroform to obtain a clear solution. The solvent is removed by evaporation under reduced pressure using a rotary evaporator or by drying at controlled temperature. The dried solid mass is pulverized and sieved to obtain the final solid dispersion.

This method is particularly useful for thermosensitive drugs because it avoids exposure to high temperatures. However, complete removal of residual organic solvents is essential to ensure product safety and regulatory compliance.⁽¹⁴⁾

3. Hot-Melt Extrusion (HME)

Hot-melt extrusion is an advanced continuous manufacturing technique widely employed in the pharmaceutical industry. The drug and polymer are blended and fed into a heated extruder, where rotating screws mix and melt the components under controlled temperature and shear. The homogeneous molten mixture is forced through a die, cooled, and milled into the desired particle size.

Hot-melt extrusion provides excellent content uniformity, reproducibility, and scalability while eliminating the need for organic solvents. It is particularly suitable for preparing amorphous solid dispersions.⁽¹⁵⁾

4. Spray Drying Method

Spray drying involves dissolving the drug and polymer in a suitable solvent followed by atomization of the solution into a stream of heated air. Rapid solvent evaporation results in the formation of fine dry particles containing molecularly dispersed drug.

This technique produces particles with high surface area, excellent flowability, rapid dissolution, and improved bioavailability. Spray drying is widely used for commercial production of amorphous solid dispersions.⁽¹⁶⁾

5. Freeze Drying (Lyophilization)

Freeze drying involves dissolving or dispersing the drug and carrier in an appropriate solvent followed by freezing at very low temperatures. Ice crystals are removed by sublimation under vacuum, producing a highly porous solid matrix.

Lyophilization minimizes thermal degradation and preserves the amorphous nature of the drug. However, the process is expensive, time-consuming, and generally limited to heat-sensitive compounds.⁽¹⁷⁾

6. Kneading Method

In the kneading method, the polymer is mixed with a small quantity of solvent to produce a paste-like mass. The drug is gradually incorporated with continuous kneading until a homogeneous mixture is obtained. The resulting mass is dried, pulverized, and sieved.

This method is simple, inexpensive, and requires minimal equipment, making it suitable for laboratory-scale preparation.⁽¹⁶⁾

7. Co-Grinding Method

Co-grinding or mechanochemical activation involves simultaneous grinding of the drug and carrier using a mortar and pestle or ball mill. Mechanical energy reduces particle size, improves intimate contact between drug and polymer, and may partially convert the crystalline drug into an amorphous state.

The technique is solvent-free, environmentally friendly, and economical.⁽¹⁷⁾

8. Supercritical Fluid Technology

Supercritical fluid technology utilizes supercritical carbon dioxide as a processing medium. Drug and polymer are dissolved or suspended in the supercritical fluid, followed by rapid expansion or solvent extraction to obtain fine particles with enhanced dissolution characteristics.

This technique produces solvent-free products with narrow particle-size distribution but requires sophisticated and expensive equipment.

9. Microwave-Assisted Method

Microwave irradiation generates rapid internal heating, allowing homogeneous melting of the drug and polymer. The molten mixture is cooled, pulverized, and sieved to produce the solid dispersion.

The method reduces processing time, improves energy efficiency, and minimizes thermal degradation compared with conventional heating.⁽¹⁸⁾

10. Electrospinning

Electrospinning is an emerging technique in which a polymeric drug solution is subjected to a high-voltage electric field to produce ultrafine nanofibers. The rapid evaporation of solvent during fiber formation yields amorphous solid dispersions with extremely high surface area and excellent dissolution characteristics.

Electrospinning is particularly useful for developing advanced drug delivery systems and personalized dosage forms.

CHARACTERIZATION TECHNIQUES OF SOLID DISPERSIONS

Characterization of solid dispersions is essential to evaluate the physicochemical properties, drug–polymer interactions, crystallinity, morphology, stability, and dissolution behavior of the formulation. Comprehensive characterization ensures the quality, performance, and reproducibility of solid dispersion systems.^(19,20,21)

1. Drug Content Determination

Drug content analysis is performed to determine the uniform distribution of the drug within the carrier matrix. An accurately weighed quantity of solid dispersion equivalent to the required amount of drug is dissolved in a suitable solvent and analyzed using UV-Visible spectrophotometry or High-Performance Liquid Chromatography (HPLC). Drug content is generally expressed as the percentage of labeled drug present in the formulation.

2. Saturation Solubility Study

Saturation solubility studies evaluate the improvement in drug solubility after formulation. Excess solid dispersion is added to distilled water or suitable dissolution media and shaken continuously for 24–48 hours at 37 ± 0.5°C until equilibrium is reached. The solution is filtered and analyzed spectrophotometrically or by HPLC. Increased saturation solubility indicates successful enhancement of drug dissolution.

3. In-vitro Dissolution Study

Dissolution testing is the most important evaluation parameter for solid dispersions. The study is performed using the USP Dissolution Apparatus I (Basket) or Apparatus II (Paddle) in suitable dissolution media maintained at 37 ± 0.5°C. Samples are withdrawn at predetermined intervals, filtered, and analyzed spectrophotometrically. Dissolution profiles of the solid dispersion are compared with those of the pure drug to assess improvement in dissolution rate.

4. Fourier Transform Infrared Spectroscopy (FTIR)

FTIR spectroscopy is employed to investigate drug–polymer compatibility and identify possible chemical interactions. The spectra of the pure drug, polymer, physical mixture, and solid dispersion are recorded over the range of 4000–400 cm?¹. The absence of significant shifts or disappearance of characteristic peaks indicates chemical compatibility, whereas changes in peak position or intensity may suggest hydrogen bonding or molecular interactions.

5. Differential Scanning Calorimetry (DSC)

Differential Scanning Calorimetry is used to evaluate the thermal behavior of solid dispersions. DSC measures heat flow associated with melting, crystallization, and glass transition. The disappearance or reduction of the drug's melting endotherm indicates conversion from the crystalline to the amorphous state, confirming successful formation of a solid dispersion.

6. Powder X-ray Diffraction (PXRD)

PXRD is used to determine the crystalline or amorphous nature of the drug within the solid dispersion. Pure crystalline drugs exhibit sharp and intense diffraction peaks, whereas amorphous systems produce broad halos with reduced peak intensity. Decreased crystallinity generally correlates with improved solubility and dissolution.

7. Scanning Electron Microscopy (SEM)

SEM is employed to examine the surface morphology, particle size, and surface characteristics of solid dispersions. SEM images reveal changes in particle shape, surface roughness, porosity, and aggregation. The disappearance of characteristic drug crystals indicates successful molecular dispersion within the carrier.

8. Transmission Electron Microscopy (TEM)

TEM provides high-resolution images of the internal structure of solid dispersions. It is useful for evaluating particle size, particle distribution, and nanoscale morphology. TEM can confirm homogeneous dispersion of drug particles within the polymeric matrix.

9. Stability Studies

Stability studies are conducted according to ICH guidelines under accelerated (40 ± 2°C/75 ± 5% RH) and long-term storage conditions. Samples are periodically evaluated for appearance, drug content, dissolution profile, crystallinity, and thermal behavior. Stability studies determine whether the amorphous drug recrystallizes during storage and ensure long-term product quality.

ADVANTAGES AND LIMITATIONS OF SOLID DISPERSION TECHNOLOGY

• Advantages

1. Improved Aqueous Solubility Solid dispersions significantly increase the apparent solubility of poorly soluble drugs by dispersing the drug within hydrophilic carriers. This facilitates rapid interaction between the drug and dissolution medium, resulting in enhanced drug solubility
2. Enhanced Dissolution Rate The drug is present in a molecularly dispersed or amorphous state with reduced particle size and increased surface area, leading to a much faster dissolution rate than the pure crystalline drug
3. Increased Oral Bioavailability Improved dissolution enhances gastrointestinal absorption, resulting in increased oral bioavailability, reduced interpatient variability, and improved therapeutic efficacy
4. Reduction in Drug Crystallinity Conversion of crystalline drug into an amorphous form increases molecular mobility and free energy, thereby improving dissolution and drug release
5. Improved Wettability Hydrophilic polymers improve the wettability of drug particles, allowing dissolution media to penetrate rapidly and dissolve the drug more efficiently
6. Uniform Drug Distribution Drug molecules are uniformly distributed throughout the polymer matrix, minimizing aggregation and ensuring consistent drug release.^(22,23)

• Limitations

1. Physical Instability The amorphous drug may recrystallize during storage because of temperature, humidity, or molecular mobility, resulting in reduced solubility and dissolution.
2. Moisture Sensitivity Many hydrophilic polymers are hygroscopic and absorb atmospheric moisture, affecting stability and performance.
3. Thermal Degradation Fusion-based methods require elevated temperatures, making them unsuitable for thermolabile drugs.
4. Residual Organic Solvents Solvent evaporation techniques may leave traces of residual solvents that require careful removal to comply with regulatory guidelines.
5. Polymer Compatibility Issues Not every polymer is compatible with every drug. Poor compatibility may lead to phase separation or instability.
6. Scale-Up Challenges Some laboratory preparation techniques are difficult to reproduce on an industrial scale.⁽²⁴⁾

FUTURE PERSPECTIVES

1. Development of novel hydrophilic polymers and polymeric blends to improve the stability of gliclazide solid dispersions.
2. Utilization of advanced manufacturing techniques such as hot-melt extrusion and spray drying for large-scale production.
3. Application of Quality by Design (QbD) and Process Analytical Technology (PAT) to optimize formulation development and manufacturing.
4. Exploration of nanotechnology-based solid dispersions to further enhance solubility, dissolution, and oral bioavailability.
5. Development of supersaturating solid dispersion systems to maintain prolonged drug supersaturation and improve absorption.
6. Investigation of three-dimensional (3D) printing technology for personalized gliclazide dosage forms.
7. Evaluation of novel carriers such as Soluplus®, copovidone, amphiphilic polymers, and polymeric surfactants for improved formulation performance.

CONCLUSION

Gliclazide is a BCS Class II antidiabetic drug with poor aqueous solubility, which limits its dissolution and oral bioavailability. Solid dispersion technology is an effective approach to overcome these limitations by improving drug wettability, reducing crystallinity, and enhancing dissolution rate. Various preparation methods and hydrophilic carriers have demonstrated significant improvements in the physicochemical and biopharmaceutical properties of gliclazide. Overall, solid dispersion technology represents a simple, reliable, and promising formulation strategy for enhancing the therapeutic efficacy and oral bioavailability of gliclazide.

REFERENCES

1. Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018;10(3):74.
2. Tekade AR, Yadav JN. A review on solid dispersion and carriers used therein for solubility enhancement of poorly water-soluble drugs. Adv Pharm Bull. 2020;10(3):359-369.
3. Mehta S, Joseph NM, Feleke F, Palani S. Improving solubility of BCS Class II drugs using solid dispersion: A review. J Drug Deliv Ther. 2014;4(3):7-13
4. Maggi L, Canobbio A, Bruni G, Musitelli G, Conte U. Improvement of the dissolution behavior of gliclazide, a slightly soluble drug, using solid dispersions. J Drug Deliv Sci Technol. 2015.
5. Ali HS, York P, Ali AMA, Blagden N. Pharmacokinetics and anti-diabetic studies of gliclazide nanosuspension. Pharmaceutics. 2022.
6. Jermain SV, Brough C, Williams RO III. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery—An update. Int J Pharm. 2018;535(1-2):379-392.
7. Kumar B. Solid dispersion—A review. PharmaTutor. 2017.
8. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract. 1991;14(Suppl 2):S21–S36. doi:10.1016/0168-8227(91)90005-X.
9. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993;46(1):92–125. doi:10.2165/00003495-199346010-00007.
10. Singh AK, Singh R. Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Rev Clin Pharmacol. 2016;9(6):839–851. doi:10.1586/17512433.2016.1159512.
11. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281–1302.
12. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47–60.
13. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water-soluble drugs. Drug Discov Today. 2007;12(23–24):1068–1075.
14. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131–144.
15. Janssens S, Van den Mooter G. Review: Physical chemistry of solid dispersions. J Pharm Pharmacol. 2009;61(12):1571–1586.
16. Baghel S, Cathcart H, O'Reilly NJ. Polymeric amorphous solid dispersions: A review of preparation, characterization and stabilization. J Pharm Pharmacol. 2016;68(1):1–18.
17. Repka MA, Langley N, DiNunzio JC. Melt Extrusion: Materials, Technology and Drug Product Design. New York: Springer; 2013.
18. Vo CLN, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm. 2013;85(3):799–813.
19. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1–12.
20. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48(1):27–42.
21. Janssens S, Van den Mooter G. Review: Physical chemistry of solid dispersions. J Pharm Pharmacol. 2009;61(12):1571–1586.
22. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47–60.
23. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water-soluble drugs. Drug Discov Today. 2007;12(23–24):1068–1075.
24. Baghel S, Cathcart H, O'Reilly NJ. Polymeric amorphous solid dispersions: A review of preparation, characterization and stabilization. J Pharm Pharmacol. 2016;68(1):1–18.